246 related articles for article (PubMed ID: 23261718)
1. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients.
Li FJ; Zhang Y; Jin GX; Yao L; Wu DQ
Immunol Lett; 2013 Feb; 150(1-2):116-22. PubMed ID: 23261718
[TBL] [Abstract][Full Text] [Related]
2. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
4. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
Zhang Q; Yang L; Liu S; Zhang M; Jin Z
Front Immunol; 2021; 12():645835. PubMed ID: 34177894
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
8. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes.
Hirano S; Iwashita Y; Sasaki A; Kai S; Ohta M; Kitano S
J Gastroenterol Hepatol; 2007 May; 22(5):690-6. PubMed ID: 17444857
[TBL] [Abstract][Full Text] [Related]
9. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
10. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
[TBL] [Abstract][Full Text] [Related]
11. [Elevated expression of lymphocyte activation gene-3 on peripheral blood CD8(+) T lymphocytes in patients with chronic hepatitis B virus infection].
Ma C; Lu Z; Wang K; Bie L; Shen Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Apr; 32(4):532-7. PubMed ID: 27053622
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma.
Pan QZ; Pan K; Zhao JJ; Chen JG; Li JJ; Lv L; Wang DD; Zheng HX; Jiang SS; Zhang XF; Xia JC
Cancer Immunol Immunother; 2013 Nov; 62(11):1675-85. PubMed ID: 24061617
[TBL] [Abstract][Full Text] [Related]
13. The CD39
Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
15. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
Liu S; Yang L; Jia S; Zhao R; Jin Z
Int Immunopharmacol; 2021 Nov; 100():108161. PubMed ID: 34555643
[TBL] [Abstract][Full Text] [Related]
16. Genetic and phenotypic difference in CD8
Wang X; He Q; Shen H; Lu XJ; Sun B
J Med Genet; 2019 Jan; 56(1):18-21. PubMed ID: 29666149
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-35 Dampens CD8
Yang L; Shao X; Jia S; Zhang Q; Jin Z
Front Immunol; 2019; 10():1032. PubMed ID: 31134088
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
19. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
